TickerTalks
Browse all tickers →
TickerTalks›$SOPH
SOSOPH

SOPHiA GENETICS S.A.

$SOPH·$700M·Medical - Healthcare Information Services·Healthcare
$8.20-3.4%YTD+80.6%1Y+91.6%
Price updated 13m ago·X counts updated 2d ago
SOSOPH
$SOPHSOPHiA GENETICS S.A.
$8.20-3.41%61 posts1×
AI analysisFundamentalsVoices on X
Loading…

On X

The complete picture of $SOPH on X — how loud the conversation is right now, how it has trended over the last two weeks, and which way the crowd is leaning.

61X posts · last 7 days
Sep 11Sep 27
Chatter Meter
1×
QuietNormal · 1×Loud

How loud $SOPH's conversation on X is versus its own normal — 1× is typical, higher means busier. Right now it's about its usual level, louder than 80% of tracked names.

Bearish sentimentAI analysisGenerated by AI from underlying data14 posts analyzed · as of 2026-09-16

$SOPH is the crypto token, and posters treat the tape as a textbook pump-and-dump: -62% in a day after a +319% run over 20 days, Binance flagging it under monitoring, and whale selling reported. Short traders are unabashedly celebrating profits, and pattern posters use $SOPH as the analog for the next dump they expect on $RESOLV and $KAT. A quiet accumulation-phase view exists but has no volume.

Read what X is saying about $SOPH

  • Bullish vs bearish call — with the AI summary of the day's posts
  • Divergence flag when the top-engagement posts argue the other side
  • How loud the conversation is versus this ticker's own normal
Free, forever. No credit card.

AI verdictAI analysisGenerated by AI from underlying data

TickerTalks' own read on what's driving $SOPH — fundamentals, momentum, or an event — and whether it agrees with the X crowd.

Driven by hypeAcceleratingAI verdict · as of 2026-09-29

The move is getting stronger, with heavier trading behind it.

Cash-burning genomics-software name up 81% year to date and near a 52-week high on real revenue growth — separately, the X cashtag is a crypto pump not the equity.

SOPHiA GENETICS is a $700M-cap Swiss clinical-genomics software company that is showing real operational progress even though it is still deeply loss-making.

  • Up 81% year to date and 92% over the last twelve months, positioned 91% of the way up its 52-week range and 13% above the 50-day moving average.
  • Q2 revenue $23M was +27% year over year, gross margin 65%, but operating margin remains minus 86% and free cash flow was minus $10M — this is not yet a self-funding business.
  • Three straight earnings misses (each by 16-24%) but the miss on the top line is narrowing, and analyst consensus for the year is roughly minus $0.94 EPS.
  • A cluster of small S-Sale filings this month (Muken, Cardoza, Menu, Xu, Van Well) totaling under $130K — routine vesting-related selling, not distribution at scale.
  • At a 7.4x trailing sales multiple with operating losses this wide, the tape needs continued revenue acceleration and a visible path to breakeven to hold current levels.

The November 3 quarter will show whether the revenue growth rate holds above 25% and whether operating loss narrows sequentially.

What to watch: November 3 print — revenue growth holding above 25%, gross margin staying above 65%, and any commentary on the path to positive operating cash given the current burn.

On the calendar: 2026-11-03 — Q3 earnings

ticker collision crypto

Read the AI verdict on $SOPH

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • Whether TickerTalks' read agrees with or diverges from the X crowd
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Cloud SaaS platform standardizing genomic data analysis for oncology and rare disease clinical decision-making worldwide.

Industry overviewAI analysisGenerated by AI from underlying data

Where Medical - Healthcare Information Services sits in its cycle right now — and what that implies for $SOPH.

Medical - Healthcare Information Services · Healthcare

No material change from last week — AI-driven clinical workflow digitization and prior-authorization automation are the structural demand drivers.

What this means for $SOPH

Partial — Cloud SaaS platform standardizing genomic data analysis for oncology and rare disease clinical decision-making worldwide.

Industry benchmark

10-name peer basket
+10.4%YTD
+2.4%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-6.6How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-48.8%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-85.0%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-7.1%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
7.4Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-137%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
66.6%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.7Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 4, 2026$-0.26$-0.21-23.8%
Q1 2026May 5, 2026$-0.27$-0.23-16.1%
Q4 2025Mar 3, 2026$-0.28$-0.24-17.9%
Q3 2025Nov 4, 2025$-0.30$-0.20-50.0%
Next earningsTue, Nov 3·consensus EPS $-0.20

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q2 FY26$23.3M+27.2%64.6%-86.0%$-0.30$-10.4M
Q1 FY26$21.7M+22.0%68.0%-79.7%$-0.27$-17.1M
Q4 FY25$21.7M+22.4%67.7%-83.1%$-0.28$-9.3M
Q3 FY25$19.5M+22.8%66.3%-91.8%$-0.30$-8.9M

Forward consensus

5-year forecast · up to 4 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$95.3M$95.1M – $95.4M-$0.94-$1.00 – -$0.904
FY27$117.9M$112.4M – $123.4M-$0.63-$0.67 – -$0.604
FY28$150.2M$141.9M – $165.8M-$0.36-$0.52 – -$0.023
FY29$193.7M$187.7M – $203.8M$0.01$0.01 – $0.011
FY30$259.0M$251.0M – $272.5M$0.53$0.51 – $0.572

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.8×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.91%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+12.7%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+50.8%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatMid float · 72.0M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today0.8% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β0.985-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellSep 21George CardozaCFO774 sh$6KSellSep 21Ross MukenCEO422 sh$4KSellSep 14Philippe MenuChief Medical Officer5.0K sh$39KSellSep 14Zhenyu XuChief Scientific Officer4.0K sh$32KSellSep 11Van Well DaanChief Legal Officer6.2K sh$47KSellSep 10Jurgi CamblongChair8.5K sh$65KSellSep 8Kathy L HibbsDirector6.3K sh$51KSellAug 27Zhenyu XuChief Scientific Officer10.0K sh$89KSellAug 25Philippe MenuChief Medical Officer5.0K sh$43KSellAug 25Kathy L HibbsDirector6.3K sh$54K
1–10 of 40
+ 4 other (4 exempts) in window

See when $SOPH insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

424B5Prospectus supplement (offering)Jun 17424B5
424B5Prospectus supplement (offering)Jun 16424B5
+ 7 other (7 6-Ks) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

SOPHiA GENETICS (SOPH) Moves 7.0% Higher: Will This Strength Last?zacks.com·11d agoWhen Unusual Volume Isn't Noise: 3 Small-Caps Sending Signalsmarketbeat.com·33d agoSOPHiA GENETICS (NASDAQ:SOPH) Sets New 1-Year High – What’s Next?defenseworld.net·36d agoSOPHiA GENETICS SA (SOPH) Q2 2026 Earnings Call Transcriptseekingalpha.com·56d agoSOPHiA GENETICS Q2 Earnings Call Highlightsmarketbeat.com·56d ago

In themes

Explore the broader themes this ticker is being talked about under.

AI Precision Medicine

More in Medical - Healthcare Information Services

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$TEM$HCAT$DOCS$TDOC$HNGE$BTSG$OPRX$HTFL
Voices on X · last 7 days

No standout posts about $SOPH on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport